ArticleFrontiers in medicine2023
DRSN4mCPred: accurately predicting sites of DNA N4-methylcytosine using deep residual shrinkage network for diagnosis and treatment of gastrointestinal cancer in the precision medicine era.
Article in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- EnDeep4mC predicts DNAGenome research · 2026Article
- Shedding light on DNA methylation and its clinical implications: the impact of long-read-based nanopore technology.Epigenetics & chromatin · 2024Review
- iDNA-OpenPrompt: OpenPrompt learning model for identifying DNA methylation.Frontiers in genetics · 2024Article
- iDNA-ITLM: An interpretable and transferable learning model for identifying DNA methylation.PloS one · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The DNA N4-methylcytosine (4mC) site levels of those suffering from digestive system cancers were higher, and the pathogenesis of digestive system cancers may also be related to the changes in DNA 4mC levels. Identifying DNA 4mC sites is a very important step in studying the analysis of biological function and cancer prediction. Extracting accurate features from DNA sequences is the key to establishing a prediction model of effective DNA 4mC sites. This study sought to develop a new predictive model, DRSN4mCPred, which aimed to improve the performance of the predicting DNA 4mC sites. Methods: The model adopted multi-scale channel attention to extract features and used attention feature fusion (AFF) to fuse features. In order to capture features information more accurately and effectively, this model utilized Deep Residual Shrinkage Network with Channel-Wise thresholds (DRSN-CW) to eliminate noise-related features and achieve a more precise feature representation, thereby, distinguishing the sites in DNA with 4mC and non-4mC. Additionally, the predictive model incorporated an inverted residual block, a Multi-scale Channel Attention Module (MS-CAM), a Bi-directional Long Short Term Memory Network (Bi-LSTM), AFF, and DRSN-CW. Results and Discussion: The results indicated the predictive model DRSN4mCPred had extremely good performance in predicting the DNA 4mC sites across different species. This paper will potentially provide support for the diagnosis and treatment of gastrointestinal cancer based on artificial intelligence in the precise medical era.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.